Originally published as JCO Early Release 10.1200/JCO.2004.03.091 on September 20 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Skates, S. J. Articles by Bast, R. C. Search for Related Content PubMed PubMed Citation Articles by Skates, S. J. Articles by Bast, R. C., Jr

Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions

From the Massachusetts General Hospital and Harvard Medical School, Boston, MA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Duke University Medical Center, Durham, NC; Johns Hopkins Medical Institutions, Baltimore, MD; Groningen University Hospital, Groningen, the Netherlands; and St Bartholomew’s Hospital, London, United Kingdom

Address reprint requests to Steven J. Skates, PhD, Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, e-mail: sskates{at}partners.org

PURPOSE: In CA-125–based ovarian cancer screening trials, overall specificity and screening sensitivity of ultrasound after an elevated CA-125 exceeded 99.6% and 70%, respectively, thereby yielding a positive predictive value (PPV) exceeding 10%. However, sensitivity for early-stage disease was only 40%. This study aims to increase preoperative sensitivity for early-stage ovarian cancer while maintaining the annual referral rate to ultrasound at 2% by combining information across CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor (M-CSF). For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%).

PATIENTS AND METHODS: Logistic regression, classification tree, and mixture discriminant analysis (MDA) models were fit to a training data set of preoperative serum measurements (63 patients, 126 healthy controls) from one center. Estimates from the training set applied to an independent validation set (60 stage I to II patients, 98 healthy controls) from two other centers provided unbiased estimates of sensitivity.

RESULTS: Preoperative sensitivities for early-stage disease of the optimal panels were 45% for CA-125II; 67% for CA-125II and CA 72-4; 70% for CA-125II, CA 72-4, and M-CSF; and 68% for all four markers (latter two results using MDA).

CONCLUSION: Efficiently combining information on CA-125II, CA 72-4, and M-CSF significantly increased preoperative early-stage sensitivity from 45% with CA-125II alone to 70%, while maintaining 98% first-line specificity. Screening trials with these markers using MDA followed by referral to ultrasound may maintain previously high levels of specificity and PPV, while significantly increasing early-stage screening sensitivity. MDA is a useful, biologically justified method for combining biomarkers.

Supported by a SPORE Grant in Ovarian Cancer 1P50 CA83639 from the National Cancer Institute, Department of Health and Human Services.

A poster presentation of preliminary results from this study was given at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				M. E. Hudson, I. Pozdnyakova, K. Haines, G. Mor, and M. Snyder Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays PNAS, October 30, 2007; 104(44): 17494 - 17499. [Abstract] [Full Text] [PDF]

				S. G Baker, B. S Kramer, M. McIntosh, B. H Patterson, Y. Shyr, and S. Skates Evaluating markers for the early detection of cancer: overview of study designs and methods Clinical Trials, February 1, 2006; 3(1): 43 - 56. [Abstract] [PDF]

				G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-Ward, and D. C. Ward Serum protein markers for early detection of ovarian cancer PNAS, May 24, 2005; 102(21): 7677 - 7682. [Abstract] [Full Text] [PDF]

				U. Matulonis, J. L. Abrahm, C.-M. Liu, and S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., March 24, 2005; 352(12): 1268 - 1269. [Full Text] [PDF]

				M. L. Hensley and D. R. Spriggs Cancer Screening: How Good Is Good Enough? J. Clin. Oncol., October 15, 2004; 22(20): 4037 - 4039. [Full Text] [PDF]